Difference between revisions of "Non-small cell lung cancer, HER2-mutated"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m
Line 16: Line 16:
 
=Metastatic disease, all lines of therapy=
 
=Metastatic disease, all lines of therapy=
 
==Trastuzumab deruxtecan monotherapy {{#subobject:7hg71v|Regimen=1}}==
 
==Trastuzumab deruxtecan monotherapy {{#subobject:7hg71v|Regimen=1}}==
 +
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen variant #1, 5.4 mg/kg {{#subobject:f3hug9|Variant=1}}===
 
===Regimen variant #1, 5.4 mg/kg {{#subobject:f3hug9|Variant=1}}===
 
{| class="wikitable sortable" style="color:white; background-color:#404040"
 
{| class="wikitable sortable" style="color:white; background-color:#404040"
Line 31: Line 32:
 
|-
 
|-
 
|}
 
|}
 +
<div class="toccolours" style="background-color:#fdcdac">
 
====Biomarker eligibility criteria====
 
====Biomarker eligibility criteria====
 
*HER2 mutations
 
*HER2 mutations
 +
</div>
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Antibody-drug conjugate therapy====
 
====Antibody-drug conjugate therapy====
−
 
 
*[[Trastuzumab deruxtecan (Enhertu)]] 5.4 mg/kg IV once on day 1
 
*[[Trastuzumab deruxtecan (Enhertu)]] 5.4 mg/kg IV once on day 1
−
 
 
'''21-day cycles'''
 
'''21-day cycles'''
−
 
+
</div></div><br>
 +
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen variant #2, 6.4 mg/kg {{#subobject:f3eig9|Variant=1}}===
 
===Regimen variant #2, 6.4 mg/kg {{#subobject:f3eig9|Variant=1}}===
 
{| class="wikitable" style="width: 60%; text-align:center;"  
 
{| class="wikitable" style="width: 60%; text-align:center;"  
Line 45: Line 48:
 
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
−
|[https://doi.org/10.1056/nejmoa2112431 Li et al. 2021 (DESTINY-Lung01)]
+
|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9066448/ Li et al. 2021 (DESTINY-Lung01)]
 
|2018-2020
 
|2018-2020
 
|style="background-color:#91cf61"|Phase 2
 
|style="background-color:#91cf61"|Phase 2
Line 54: Line 57:
 
|-
 
|-
 
|}
 
|}
 +
<div class="toccolours" style="background-color:#fdcdac">
 
====Biomarker eligibility criteria====
 
====Biomarker eligibility criteria====
 
*HER2 mutations
 
*HER2 mutations
 +
</div>
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Antibody-drug conjugate therapy====
 
====Antibody-drug conjugate therapy====
−
 
 
*[[Trastuzumab deruxtecan (Enhertu)]] 6.4 mg/kg IV once on day 1
 
*[[Trastuzumab deruxtecan (Enhertu)]] 6.4 mg/kg IV once on day 1
−
 
 
'''21-day cycles'''
 
'''21-day cycles'''
−
 
+
</div></div>
 
===References===
 
===References===
−
#'''DESTINY-Lung01:''' Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Pérol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Jänne PA; DESTINY-Lung01 Trial Investigators. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022 Jan 20;386(3):241-251. Epub 2021 Sep 18. [https://doi.org/10.1056/nejmoa2112431 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/34534430/ PubMed] NCT03505710
+
#'''DESTINY-Lung01:''' Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Pérol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Jänne PA; DESTINY-Lung01 Trial Investigators. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022 Jan 20;386(3):241-251. Epub 2021 Sep 18. [https://doi.org/10.1056/nejmoa2112431 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9066448/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/34534430/ PubMed] NCT03505710
 
#'''DESTINY-Lung02:''' NCT04644237
 
#'''DESTINY-Lung02:''' NCT04644237
−
 
 
[[Category:Non-small cell lung cancer regimens]]
 
[[Category:Non-small cell lung cancer regimens]]
 
[[Category:Biomarker-specific pages]]
 
[[Category:Biomarker-specific pages]]
 
[[Category:Non-small cell lung cancers]]
 
[[Category:Non-small cell lung cancers]]

Revision as of 01:27, 27 February 2023

Back to Top

Section editor transclusions Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.

3 regimens on this page
4 variants on this page


Guidelines

ASCO

Metastatic disease, all lines of therapy

Trastuzumab deruxtecan monotherapy

Regimen variant #1, 5.4 mg/kg

FDA-recommended dose
Study Years of enrollment Evidence
Awaiting publication (DESTINY-Lung02) 2021-ongoing Phase 2 (RT)

Biomarker eligibility criteria

  • HER2 mutations

Antibody-drug conjugate therapy

21-day cycles


Regimen variant #2, 6.4 mg/kg

Study Years of enrollment Evidence
Li et al. 2021 (DESTINY-Lung01) 2018-2020 Phase 2
Awaiting publication (DESTINY-Lung02) 2021-ongoing Phase 2

Biomarker eligibility criteria

  • HER2 mutations

Antibody-drug conjugate therapy

21-day cycles

References

  1. DESTINY-Lung01: Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Pérol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Jänne PA; DESTINY-Lung01 Trial Investigators. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022 Jan 20;386(3):241-251. Epub 2021 Sep 18. link to original article contains dosing details in manuscript link to PMC article PubMed NCT03505710
  2. DESTINY-Lung02: NCT04644237
Retrieved from "https://hemonc.org/w/index.php?title=Non-small_cell_lung_cancer,_HER2-mutated&oldid=66553"